Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07062549 · ClinicalTrials.gov registry record · Phase 1
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
A Phase 1 study of Renal Cell Carcinoma (Kidney Cancer), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT07062549: Recruiting Phase 1 study of Renal Cell Carcinoma (Kidney Cancer), sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT07062549 is a Phase 1 study of Renal Cell Carcinoma (Kidney Cancer) that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07062549, a Phase 1 study of Renal Cell Carcinoma (Kidney Cancer), is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan
Primary Outcome
To evaluate the safety, tolerability, and feasibility of SPECT/CT imaging with 111In-XYIMSR-01 measured by all adverse events according to CTCAE version 5.
Conditions Studied
Interventions
- DRUG 111In-XYIMSR-01
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-01-26 |
| Est. Completion | 2029-07 |
| Phase | Phase 1 |
What NCT07062549 shows while recruiting
NCT07062549 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Renal Cell Carcinoma (Kidney Cancer) appearing as the primary indexed condition, and to 1 intervention - of which 111In-XYIMSR-01 is the first listed.
NCT07062549 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT07062549 about?
NCT07062549 is a clinical study titled "Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell". This study is being done to determine if the investigational radiotracer called 111In-XYIMSR-01 is helpful in detecting clear cell renal cell carcinoma tissue in your body when used during a SPECT-CT Scan
What is the current status of trial NCT07062549?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-01-26. Estimated completion is 2029-07.
What conditions does trial NCT07062549 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma (Kidney Cancer).
What interventions are being tested in trial NCT07062549?
The interventions under investigation include: 111In-XYIMSR-01 (DRUG).
Who is sponsoring clinical trial NCT07062549?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07062549 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma (Kidney Cancer)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07062549's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI